Back to the list
Congress: ECR25
Poster Number: C-14720
Type: Poster: EPOS Radiologist (educational)
Authorblock: P. Suphannapornsuk, V. Charoonratana, N. Sanghan; Songkhla/TH
Disclosures:
Praphatsorn Suphannapornsuk: Author: none
Vorawan Charoonratana: Advisory Board: none
Nuttha Sanghan: Advisory Board: none
Keywords: Neuroradiology brain, MR, Imaging sequences, Laboratory tests, Outcomes analysis, Endocrine disorders
References
  1. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf). 2006;65(2):265-73.
  2. Fukuhara N, Nishiyama M, Iwasaki Y. Update in Pathogenesis, Diagnosis, and Therapy of Prolactinoma. Cancers (Basel). 2022;14(15).
  3. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocrine reviews. 2006;27(5):485-534.
  4. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-88.
  5. Varlamov EV, Hinojosa-Amaya JM, Fleseriu M. Magnetic resonance imaging in the management of prolactinomas; a review of the evidence. Pituitary. 2020;23:16-26.
  6. Potorac I, Petrossians P, Daly AF, Schillo F, Ben Slama C, Nagi S, et al. Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. Endocr Relat Cancer. 2015;22(2):169-77.
  7. Heck A, Emblem KE, Casar-Borota O, Bollerslev J, Ringstad G. Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly. Endocrine. 2016;52:333-43.
  8. Heck A, Emblem KE, Casar-Borota O, Ringstad G, Bollerslev J. MRI T2 characteristics in somatotroph adenomas following somatostatin analog treatment in acromegaly. Endocrine. 2016;53:327-30.
  9. Coopmans EC, van der Lely AJ, Schneiders JJ, Neggers SJ. Potential antitumour activity of pasireotide on pituitary tumours in acromegaly. The Lancet Diabetes & Endocrinology. 2019;7(6):425-6.
  10. Hagiwara A, Inoue Y, Wakasa K, Haba T, Tashiro T, Miyamoto T. Comparison of growth hormone–producing and non–growth hormone–producing pituitary adenomas: imaging characteristics and pathologic correlation. Radiology. 2003;228(2):533-8.
  11. Lundin P, Bergström K, Nyman R, Lundberg PO, Muhr C. Macroprolactinomas: serial MR imaging in long-term bromocriptine therapy. American journal of neuroradiology. 1992;13(5):1279-91.
  12. Delgrange E, Daems T, Verhelst J, Abs R, Maiter D. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. European Journal of Endocrinology. 2009;160(5):747-52.
  13. Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. The Journal of Clinical Endocrinology & Metabolism. 2000;85(6):2247-52.
  14. Lombardi M, Lupi I, Cosottini M, Rossi G, Manetti L, Raffaelli V, et al. Lower prolactin levels during cabergoline treatment are associated to tumor shrinkage in prolactin secreting pituitary adenoma. Hormone and Metabolic Research. 2014;46(13):939-42.
  15. Bonneville J-F, Bonneville F, Cattin F, Nagi S. MRI of the Pituitary Gland. Springer; 2016.
  16. Burlacu MC, Maiter D, Duprez T, Delgrange E. T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists. Endocrine. 2019;63(2):323-31.
  17. Kreutz J, Vroonen L, Cattin F, Petrossians P, Thiry A, Rostomyan L, et al. Intensity of prolactinoma on T2-weighted magnetic resonance imaging: towards another gender difference. Neuroradiology. 2015;57:679-84.
  18. Kamimura K, Nakajo M, Bohara M, Nagano D, Fukukura Y, Fujio S, et al. Consistency of Pituitary Adenoma: Prediction by Pharmacokinetic Dynamic Contrast-Enhanced MRI and Comparison with Histologic Collagen Content. Cancers (Basel). 2021;13(15).
  19. Dogansen SC, Yalin GY, Tanrikulu S, Tekin S, Nizam N, Bilgic B, et al. Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas. Pituitary. 2018;21:347-54.
  20. Liu W, Zahr RS, McCartney S, Cetas JS, Dogan A, Fleseriu M. Clinical outcomes in male patients with lactotroph adenomas who required pituitary surgery: a retrospective single center study. Pituitary. 2018;21:454-62.
  21. Bonneville J-F, Bonneville F, Cattin F, Nagi S, Bonneville F. Silent corticotroph pituitary adenoma. MRI of the Pituitary Gland. 2016:113-6.
  22. Faje A, Chunharojrith P, Nency J, Biller BM, Swearingen B, Klibanski A. Dopamine agonists can reduce cystic prolactinomas. The Journal of Clinical Endocrinology & Metabolism. 2016;101(10):3709-15.

    23.  23.Hulley SB, Cummings SR, Browner WS, Grady DG, Newman TB. Designing clinical research. 4th ed. Philadelphia (PA): Lippincott Williams and Wilkins; 2013.
GALLERY